DNA demethylating agents represent a therapeutic opportunity for synovial sarcoma [RNA-Seq]
RNA-seq (gene expression) · human · 10 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 10 samples: 5 conditions, mostly in duplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- DNA demethylating agents suppress preclinical models of synovial sarcomaThe Journal of clinical investigation · 2025
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE291301_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1232796 and SRA study SRP568490. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 10 samples.
How we read this: 5 replicated groups read from 10 sample titles; they account for 10 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8833133 HSSY, Decitabine, R1 HSSY, Decitabine,
- GSM8833134 HSSY, Decitabine, R2 HSSY, Decitabine,
- GSM8833135 HSSY, DMSO, R1 HSSY, DMSO,
- GSM8833136 HSSY, DMSO, R2 HSSY, DMSO,
- GSM8833137 HSSY, sgCTRL, R1 HSSY, sgCTRL,
- GSM8833138 HSSY, sgCTRL, R2 HSSY, sgCTRL,
- GSM8833139 HSSY, sgDNMT1-a, R1 HSSY, sgDNMT1-a,
- GSM8833140 HSSY, sgDNMT1-a, R2 HSSY, sgDNMT1-a,
- GSM8833141 HSSY, sgDNMT1-b, R1 HSSY, sgDNMT1-b,
- GSM8833142 HSSY, sgDNMT1-b, R2 HSSY, sgDNMT1-b,
- GSE235738 Alveolar Soft Part Sarcoma is driven by ASPSCR1::TFE3-dependent and therapeutically targetable transcriptional programs [RNA-Seq] 35 samples shares therapeutic, sarcoma, rna-seq
- GSE309595 Longitudinal Analysis of Multiple Myeloma: Therapeutic Response and Immune Microenvironment Dynamics in the Context of Tumor Heterogeneity [scRNA-seq] 270 samples shares therapeutic, rna-seq
- GSE294016 A macrophage-predominant, immunosuppressive immune microenvironment and subtype-specific therapeutic vulnerabilities in advanced salivary gland cancer [bulk RNA-seq] 95 samples shares therapeutic, rna-seq
- GSE293952 Hypoxia shapes both therapeutic response and resistance in metastatic clear cell renal cell carcinoma [bulk RNA-seq] 61 samples shares therapeutic, rna-seq
- GSE335924 RNA-seq Identifies FOS as a Potential Therapeutic Target Activating Neural Stem Cells via miR-21/SOX2 Pathway in Hypertensive Intracerebral Hemorrhage 53 samples shares therapeutic, rna-seq
- GSE290805 Meningioma microenvironment harbors a rich immune landscape with therapeutic implications (Bulk RNA-seq part) 47 samples shares therapeutic, rna-seq
- GSE276695 Chemotherapeutic agents and leucine deprivation induce codon-biased aberrant protein production in cancer 24 samples shares therapeutic, agents
- GSE285944 Divergent therapeutic and prognostic impacts of immunogenic features in undifferentiated pleomorphic sarcoma and myxofibrosarcoma 23 samples shares therapeutic, sarcoma
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.